Evidence map›Paper›PMID 30951192›Full record

ArticleInternational journal of cancer2020

Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case-control sets from EPIC.

Julie A Schmidt, Georgina K Fensom, Sabina Rinaldi, Augustin Scalbert, Paul N Appleby, David Achaintre, Audrey Gicquiau, Marc J Gunter, Pietro Ferrari, Rudolf Kaaks and 20 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Lipid metabolism, microglia, and stroke.Neural regeneration research · 2026
    Article
  6. Article
  7. Observational
  8. Identifying Metabolomic Mediators of the Physical Activity and Colorectal Cancer Relationship.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Characteristics of Cancer Epidemiology Studies That Employ Metabolomics: A Scoping Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  16. Review
  17. Targeting lipid metabolism in metastatic prostate cancer.Therapeutic advances in medical oncology · 2023
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 16 institutions in 9 countries.

Julie A SchmidtCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-7733-8750
Georgina K FensomCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Sabina RinaldiInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-6846-1204
Augustin ScalbertInternational Agency for Research on Cancer, Lyon, France.
Paul N ApplebyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
David AchaintreInternational Agency for Research on Cancer, Lyon, France.
Audrey GicquiauInternational Agency for Research on Cancer, Lyon, France.
Marc J GunterInternational Agency for Research on Cancer, Lyon, France.
Pietro FerrariInternational Agency for Research on Cancer, Lyon, France.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Tilman KühnDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heiner BoeingDepartment of Epidemiology, German Institute of Human Nutrition (DIfE) Potsdam-Rehbrücke, Nuthetal, Germany.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece.
Anna KarakatsaniHellenic Health Foundation, Athens, Greece.
Eleni PeppaHellenic Health Foundation, Athens, Greece.
Domenico PalliCancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Sabina SieriEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.ORCID 0000-0001-5201-172X
Rosario TuminoCancer Registry and Histopathology Department, "Civic - M.P.Arezzo" Hospital, Azienda Sanitaria Provinciale Di Ragusa (ASP), Ragusa, Italy.
Bas Bueno-de-MesquitaDepartment for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Antonio AgudoUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Maria-Jose SánchezCIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
María-Dolores ChirlaqueCIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Eva ArdanazCIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Nerea LarrañagaCIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Aurora Perez-CornagoCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Nada AssiInternational Agency for Research on Cancer, Lyon, France.
Elio RiboliDepartment of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Konstantinos K TsilidisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Centre international de recherche sur le cancer · FRUniversity of Oxford · GBGerman Cancer Research Center · DEHellenic Health Foundation · GRUniversity of Ioannina · GRAgenzia Regionale Sanitaria della Puglia · ITBasque Government · ESFondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Institute of Human Nutrition · DEInstitut d'Investigació Biomédica de Bellvitge · ESInstituto de Salud Pública de Navarra · ESInstituto Murciano de Investigación Biosanitaria · ESNational and Kapodistrian University of Athens · GRPrevention Institute · USUniversidad de Granada · ESUniversity Medical Center Utrecht · NL

Funding

Cancer Research UK 14136Cancer Research UK 19170Cancer Research UK 29017Cancer Research UK C570/A16491Cancer Research UK C8221/A19170Medical Research Council 1000143Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1World Health Organization 001
6 · The paper itself

Abstract

Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR

Indexed as

AgedBiomarkers, TumorCase-Control StudiesFollow-Up StudiesHumansMaleMetabolomicsMiddle AgedNeoplasm StagingNutrition AssessmentPhosphatidylcholinesProspective StudiesProstateProstatic NeoplasmsRisk FactorsSphingomyelinsBiomarkers, TumorPhosphatidylcholinesSphingomyelinsepidemiologymetabolomicsprostate cancer risktreelet transform

Identifiers

PMID30951192
PMCPMC6916595
OpenAlexW2931486588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.